AstraZeneca and Amgen report 58% lower death risk with IMFINZI and tarlatamab in small-cell lung cancer
AstraZeneca PLC (NASDAQ: AZN) and Amgen Inc. (NASDAQ: AMGN) have reported Phase 3 findings showing that IMFINZI (durvalumab) combined with IMDELLTRA (tarlatamab-dlle) reduced the hazard of death by 58% compared with IMFINZI alone as first-line maintenance treatment for extensive-stage small-cell lung cancer. Presented at the European Society for Medical Oncology Congress 2026 on October 24